Document headingTherapeutic rationale for low dose DOXEPIN (cas 1668-19-5) in insomnia patients
-
Add time:09/24/2019 Source:sciencedirect.com
Histamine is an excitatory neurotransmitter in central nervous system. It plays an important role in the regulation of the sleep-wake cycle. Antidepressant with sleep-promoting effects, for example, DOXEPIN (cas 1668-19-5), promotes sleep not through a sedative action but through resynchronisation of circadian cycle. The stimulation of the H1 receptor is thought to play an important role in mediating arousal. Doxepin has a high affinity for the H1 receptor, making it a selective H1 antagonist at low dose and it has been shown to display sedating properties. Compared to other sedative antidepressant, low dose doxepin is the only tricyclic drug which has been evaluated by well-designed, randomised, double blind, placebo controlled studies in both adult and elderly patients. Doxepin is not designated as controlled substance/unscheduled drugs and thus may be of special advantage to use in patients with a history of substance abuse. Hence, well-documented therapeutic efficacy, tolerability and lack of important adverse effects make the low dose doxepin as a unique, rational drug for the treatment of insomnia in adult and elderly patients.
We also recommend Trading Suppliers and Manufacturers of DOXEPIN (cas 1668-19-5). Pls Click Website Link as below: cas 1668-19-5 suppliers
Prev:Comparing DOXEPIN (cas 1668-19-5) cream to oral antihistamines for the treatment of itch in burn patients: A multi-center triple-blind randomized controlled trial
Next:Original Research ArticleHighly sensitive LC–MS/MS method to estimate DOXEPIN (cas 1668-19-5) and its metabolite norDOXEPIN (cas 1668-19-5) in human plasma for a bioequivalence study) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research paperAntidepressant polypharmacy and the potential of pharmacokinetic interactions: DOXEPIN (cas 1668-19-5) but not mirtazapine causes clinically relevant changes in venlafaxine metabolism10/01/2019
- Physicochemical evaluation and non-isothermal kinetic study of the drug–excipient interaction between DOXEPIN (cas 1668-19-5) and lactose09/27/2019
- Clinical reviewDOXEPIN (cas 1668-19-5) for insomnia: A systematic review of randomized placebo-controlled trials09/26/2019
- Original Research ArticleHighly sensitive LC–MS/MS method to estimate DOXEPIN (cas 1668-19-5) and its metabolite norDOXEPIN (cas 1668-19-5) in human plasma for a bioequivalence study09/25/2019
- Comparing DOXEPIN (cas 1668-19-5) cream to oral antihistamines for the treatment of itch in burn patients: A multi-center triple-blind randomized controlled trial09/10/2019